PEGylated Interferon-alpha2b: a Branched 40K Polyethylene Glycol Derivative

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2005 Aug 4

PMID 16078148

Citations 20

Authors

Jose Ramon

Vivian Saez

Reynier Baez

Raymersy Aldana

Eugenio Hardy

Affiliations

Soon will be listed here.

Abstract

Purpose: The conjugation of interferon-alpha2b (IFN-alpha2b) to a branched-chain (40,000) polyethylene glycol (PEG2,40K) was studied.

Methods: We studied the conjugation of IFN-alpha2b at different pH values (6.5, 7, and 8), using the PEG2,40K reagent in either solution or solid state. MonoPEGylated interferon was isolated by ion-exchange chromatography and characterized using (1) sodium dodecyl sulfate-polyacrylamide gel electrophoresis, (2) cation exchange high-performance liquid chromatography, (3) bicinchoninic acid protein assay, (4) enzyme-linked immunosorbent assay, (5) cell-based bioassays, (6) thermal stability (at 60 degrees C), (7) tryptic digestion, and (8) pharmacokinetics in rats.

Results: PEGylation reaction gave 30-55% PEG2,40K-IFN-alpha2b, 1-10% polyPEGylated interferon, and 35-70% unmodified IFN-alpha2b. Compared to the polyPEGylated IFN-alpha2b species, the pure (96%) monoPEGylated conjugate retained a significantly higher bioactivity (IU/mg): 1.7x10(4)+/-8.5x10(3) vs. 2.8x10(6)+/-1.4x10(6) for antiviral and 1.9x10(4)+/-9.5x10(3) vs. 3.1x10(6)+/-1.6x10(6) for antiproliferative activity. Immunorecognition against IFN was reduced by the PEG2,40K moiety in the conjugate. This monoPEGylated IFN-alpha2b, which migrated as a single band in gel electrophoresis, was found to be a heterogeneous, complex mixture of different positional isomers. PEGylation markedly enhanced both the resistance to tryptic degradation and the thermal stability of IFN-alpha2b. The serum half-life of 40K PEG-IFN was 330-fold longer, while plasma residence time was increased 708 times compared to native IFN.

Conclusion: The PEG2,40K conjugate of IFN-alpha2b has increased in vitroand in vivo stability as compared to the native cytokine.

Citing Articles

The importance of IFNα2A (Roferon-A) in HSV-1 latency and T cell exhaustion in ocularly infected mice.

Wang S, Jaggi U, Katsumata M, Ghiasi H PLoS Pathog. 2024; 20(10):e1012612.

PMID: 39352890 PMC: 11469491. DOI: 10.1371/journal.ppat.1012612.

An organometallic swap strategy for bottlebrush polymer-protein conjugate synthesis.

Liu B, Rodriguez J, Kilgallon L, Wang W, Wang Y, Wang A Chem Commun (Camb). 2024; 60(31):4238-4241.

PMID: 38529790 PMC: 11008127. DOI: 10.1039/d4cc00293h.

Forms and Methods for Interferon's Encapsulation.

Ramos T, Villacis-Aguirre C, Vispo N, Santiago Padilla L, Pedroso Santana S, Parra N Pharmaceutics. 2021; 13(10).

PMID: 34683824 PMC: 8538586. DOI: 10.3390/pharmaceutics13101533.

Exploring a combined Escherichia coli-based glycosylation and in vitro transglycosylation approach for expression of glycosylated interferon alpha.

Prabhu S, Yang Q, Tong X, Wang L Bioorg Med Chem. 2021; 33:116037.

PMID: 33515919 PMC: 7923244. DOI: 10.1016/j.bmc.2021.116037.

Nanoconjugation and Encapsulation Strategies for Improving Drug Delivery and Therapeutic Efficacy of Poorly Water-Soluble Drugs.

Tran T, Tran P Pharmaceutics. 2019; 11(7).

PMID: 31295947 PMC: 6680391. DOI: 10.3390/pharmaceutics11070325.

References

Grace M, Youngster S, GITLIN G, Sydor W, Xie L, Westreich L . Structural and biologic characterization of pegylated recombinant IFN-alpha2b. J Interferon Cytokine Res. 2002; 21(12):1103-15. DOI: 10.1089/107999001317205240. View

Laemmli U . Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227(5259):680-5. DOI: 10.1038/227680a0. View

von Gabain A, Lundgren E, Ohlsson M, Holmgren E, Josephsson S, Alkan S . Three human interferon-alpha 2 subvariants disclose structural and functional differences. Eur J Biochem. 1990; 190(2):257-61. DOI: 10.1111/j.1432-1033.1990.tb15570.x. View

Monkarsh S, Ma Y, Aglione A, Bailon P, Ciolek D, DeBarbieri B . Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity. Anal Biochem. 1997; 247(2):434-40. DOI: 10.1006/abio.1997.2128. View

Seely J, Richey C . Use of ion-exchange chromatography and hydrophobic interaction chromatography in the preparation and recovery of polyethylene glycol-linked proteins. J Chromatogr A. 2001; 908(1-2):235-41. DOI: 10.1016/s0021-9673(00)00739-1. View

Harris J, Chess R . Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003; 2(3):214-21. DOI: 10.1038/nrd1033. View

Kontsek P, Liptakova H, Kontsekova E . Immunogenicity of interferon-alpha 2 in therapy: structural and physiological aspects. Acta Virol. 2000; 43(1):63-70. View

Smith P, Krohn R, Hermanson G, Mallia A, Gartner F, Provenzano M . Measurement of protein using bicinchoninic acid. Anal Biochem. 1985; 150(1):76-85. DOI: 10.1016/0003-2697(85)90442-7. View

Wiechelman K, Braun R, Fitzpatrick J . Investigation of the bicinchoninic acid protein assay: identification of the groups responsible for color formation. Anal Biochem. 1988; 175(1):231-7. DOI: 10.1016/0003-2697(88)90383-1. View

10.

Hinds K, Kim S . Effects of PEG conjugation on insulin properties. Adv Drug Deliv Rev. 2002; 54(4):505-30. DOI: 10.1016/s0169-409x(02)00025-x. View

11.

Bailon P, Palleroni A, Schaffer C, Spence C, Fung W, Porter J . Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem. 2001; 12(2):195-202. DOI: 10.1021/bc000082g. View

12.

Kinstler O, Brems D, Lauren S, Paige A, Hamburger J, Treuheit M . Characterization and stability of N-terminally PEGylated rhG-CSF. Pharm Res. 1996; 13(7):996-1002. DOI: 10.1023/a:1016042220817. View

13.

Siemers R, Hensley L, Ozer H . Localization of the receptor binding site of IFN-alpha 2b. J Immunol. 1988; 141(5):1550-5. View

14.

Lindsay K, Trepo C, Heintges T, Shiffman M, Gordon S, Hoefs J . A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001; 34(2):395-403. DOI: 10.1053/jhep.2001.26371. View

15.

Monfardini C, Schiavon O, Caliceti P, Morpurgo M, Harris J, Veronese F . A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug Chem. 1995; 6(1):62-9. DOI: 10.1021/bc00031a006. View

16.

Diwan M, Park T . Stabilization of recombinant interferon-alpha by pegylation for encapsulation in PLGA microspheres. Int J Pharm. 2003; 252(1-2):111-22. DOI: 10.1016/s0378-5173(02)00636-1. View

17.

Wills R . Clinical pharmacokinetics of interferons. Clin Pharmacokinet. 1990; 19(5):390-9. DOI: 10.2165/00003088-199019050-00003. View

18.

Koumenis I, Shahrokh Z, Leong S, Hsei V, Deforge L, Zapata G . Modulating pharmacokinetics of an anti-interleukin-8 F(ab')(2) by amine-specific PEGylation with preserved bioactivity. Int J Pharm. 2000; 198(1):83-95. DOI: 10.1016/s0378-5173(99)00458-5. View

19.

Wang Y, Youngster S, Grace M, Bausch J, Bordens R, Wyss D . Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev. 2002; 54(4):547-70. DOI: 10.1016/s0169-409x(02)00027-3. View

20.

Baron S, Tyring S, Fleischmann Jr W, Coppenhaver D, Niesel D, Klimpel G . The interferons. Mechanisms of action and clinical applications. JAMA. 1991; 266(10):1375-83. DOI: 10.1001/jama.266.10.1375. View